

# **Product** Data Sheet

#### GAC0003A4

Cat. No.:HY-160038CAS No.:929492-71-7Molecular Formula: $C_{20}H_{24}N_2O_3$ Molecular Weight:340.42

Target: LXR

Pathway: Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 125 mg/mL (367.19 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.9375 mL	14.6877 mL	29.3755 mL
	5 mM	0.5875 mL	2.9375 mL	5.8751 mL
	10 mM	0.2938 mL	1.4688 mL	2.9375 mL

Please refer to the solubility information to select the appropriate solvent.

### **BIOLOGICAL ACTIVITY**

Description

GAC0003A4 is an LXR inverse agonist that inhibits LXR transcriptional activity. GAC0003A4 also efficiently degrades LXR $\beta$  protein. GAC0003A4 has the potential to be used in advanced pancreatic cancer and other refractory malignancies<sup>[1]</sup>.

## **REFERENCES**

[1]. Karaboga H, et al. Screening of Focused Compound Library Targeting Liver X Receptors in Pancreatic Cancer Identified Ligands with Inverse Agonist and Degrader Activity. ACS Chem Biol. 2020 Nov 20;15(11):2916-2928.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA